- Home
- PRTC vs RPAY Comparison
PRTC vs RPAY Comparison
Compare PRTC & RPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTC
- RPAY
- Stock Information
- Founded
- PRTC 2015
- RPAY 2006
- Country
- PRTC United States
- RPAY United States
- Employees
- PRTC N/A
- RPAY N/A
- Industry
- PRTC Biotechnology: Pharmaceutical Preparations
- RPAY Business Services
- Sector
- PRTC Health Care
- RPAY Consumer Discretionary
- Exchange
- PRTC Nasdaq
- RPAY Nasdaq
- Market Cap
- PRTC 435.0M
- RPAY 469.0M
- IPO Year
- PRTC N/A
- RPAY N/A
- Fundamental
- Price
- PRTC $17.26
- RPAY $4.65
- Analyst Decision
- PRTC
- RPAY Buy
- Analyst Count
- PRTC 0
- RPAY 9
- Target Price
- PRTC N/A
- RPAY $7.22
- AVG Volume (30 Days)
- PRTC 3.7K
- RPAY 799.7K
- Earning Date
- PRTC 08-28-2025
- RPAY 11-11-2025
- Dividend Yield
- PRTC N/A
- RPAY N/A
- EPS Growth
- PRTC N/A
- RPAY N/A
- EPS
- PRTC 0.20
- RPAY N/A
- Revenue
- PRTC $6,391,000.00
- RPAY $310,367,000.00
- Revenue This Year
- PRTC N/A
- RPAY $0.04
- Revenue Next Year
- PRTC N/A
- RPAY $7.84
- P/E Ratio
- PRTC $8.54
- RPAY N/A
- Revenue Growth
- PRTC 1265.60
- RPAY 1.45
- 52 Week Low
- PRTC $13.30
- RPAY $3.59
- 52 Week High
- PRTC $24.99
- RPAY $9.75
- Technical
- Relative Strength Index (RSI)
- PRTC 46.41
- RPAY 37.78
- Support Level
- PRTC $17.63
- RPAY $4.55
- Resistance Level
- PRTC $18.17
- RPAY $4.80
- Average True Range (ATR)
- PRTC 0.21
- RPAY 0.20
- MACD
- PRTC -0.07
- RPAY -0.05
- Stochastic Oscillator
- PRTC 15.66
- RPAY 19.50
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.